The Zhitong Finance App learned that on Monday, Vaxcyte (PCVX.US) jumped more than 50%. As of press release, the increase was about 53%, with a market value of 12.8 billion US dollars. According to the news, the company's pneumococcal vaccine reached late-stage clinical trial targets. According to the company's assessment, VAX-31, a 31-valent pneumococcal conjugate vaccine in the research stage, achieved positive top-line results in the critical phase III OPUS-1 trial. The trial assessed the safety, tolerability, and immunogenicity of the vaccine candidate in adults to prevent invasive pneumococcal disease and pneumococcal pneumonia. In the OPUS-1 trial, VAX-31 reached all pre-defined common primary immunogenic endpoints in subjects age 50 and older. The results of these tests will lay the foundation for a biological product license application to be submitted to the US Food and Drug Administration soon.

The Zhitong Finance App learned that on Monday, Vaxcyte (PCVX.US) jumped more than 50%. As of press release, the increase was about 53%, with a market value of 12.8 billion US dollars. According to the news, the company's pneumococcal vaccine reached late-stage clinical trial targets. According to the company's assessment, VAX-31, a 31-valent pneumococcal conjugate vaccine in the research stage, achieved positive top-line results in the critical phase III OPUS-1 trial. The trial assessed the safety, tolerability, and immunogenicity of the vaccine candidate in adults to prevent invasive pneumococcal disease and pneumococcal pneumonia. In the OPUS-1 trial, VAX-31 reached all pre-defined common primary immunogenic endpoints in subjects age 50 and older. The results of these tests will lay the foundation for a biological product license application to be submitted to the US Food and Drug Administration soon.